VanEck Associates’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.59M | Sell |
34,505
-12,597
| -27% | -$994K | ﹤0.01% | 938 |
|
|
2025
Q4 | $3.73M | Sell |
47,102
-64,717
| -58% | -$4.87M | ﹤0.01% | 873 |
|
|
2025
Q3 | $7.32M | Buy |
111,819
+38,202
| +52% | +$1.87M | 0.01% | 638 |
|
|
2025
Q2 | $2.91M | Buy |
73,617
+71,460
| +3,313% | +$2.34M | ﹤0.01% | 895 |
|
|
2025
Q1 | $65K | Sell |
2,157
-59,462
| -96% | -$1.95M | ﹤0.01% | 1296 |
|
|
2024
Q4 | $2.15M | Buy |
61,619
+2,613
| +4% | +$97.7K | ﹤0.01% | 934 |
|
|
2024
Q3 | $2.27M | Buy |
59,006
+8,742
| +17% | +$407K | ﹤0.01% | 898 |
|
|
2024
Q2 | $2.4M | Sell |
50,264
-40,837
| -45% | -$1.67M | ﹤0.01% | 829 |
|
|
2024
Q1 | $3.95M | Buy |
91,101
+25,270
| +38% | +$1.2M | 0.01% | 668 |
|
|
2023
Q4 | $3.33M | Buy |
65,831
+1,144
| +2% | +$54.8K | 0.01% | 657 |
|
|
2023
Q3 | $2.93M | Buy |
64,687
+33,326
| +106% | +$1.37M | 0.01% | 639 |
|
|
2023
Q2 | $1.29M | Buy |
31,361
+12,186
| +64% | +$468K | ﹤0.01% | 810 |
|
|
2023
Q1 | $685K | Buy |
19,175
+7,133
| +59% | +$268K | ﹤0.01% | 923 |
|
|
2022
Q4 | $455K | Buy |
12,042
+10,625
| +750% | +$447K | ﹤0.01% | 942 |
|
|
2022
Q3 | $63K | Buy |
+1,417
| New | +$59.7K | ﹤0.01% | 1243 |
|
|
2021
Q3 | – | Sell |
-147,383
| Closed | -$5.88M | – | 1309 |
|
|
2021
Q2 | $5.88M | Sell |
147,383
-22,609
| -13% | -$886K | 0.01% | 438 |
|
|
2021
Q1 | $7.64M | Buy |
169,992
+43,349
| +34% | +$2.42M | 0.02% | 378 |
|
|
2020
Q4 | $7.16M | Buy |
126,643
+725
| +0.6% | +$36.1K | 0.02% | 347 |
|
|
2020
Q3 | $5.97M | Sell |
125,918
-17,011
| -12% | -$945K | 0.02% | 336 |
|
|
2020
Q2 | $8.43M | Buy |
142,929
+61,163
| +75% | +$3.4M | 0.03% | 280 |
|
|
2020
Q1 | $3.87M | Sell |
81,766
-22,195
| -21% | -$1.24M | 0.02% | 363 |
|
|
2019
Q4 | $6.28M | Sell |
103,961
-1,257
| -1% | -$74.9K | 0.02% | 335 |
|
|
2019
Q3 | $6.3M | Buy |
105,218
+1,336
| +1% | +$87.1K | 0.03% | 298 |
|
|
2019
Q2 | $6.68M | Sell |
103,882
-18,491
| -15% | -$1.31M | 0.03% | 282 |
|
|
2019
Q1 | $9.93M | Sell |
122,373
-10,503
| -8% | -$678K | 0.05% | 216 |
|
|
2018
Q4 | $7.18M | Sell |
132,876
-4,595
| -3% | -$234K | 0.04% | 253 |
|
|
2018
Q3 | $7.09M | Buy |
137,471
+775
| +0.6% | +$36.4K | 0.03% | 276 |
|
|
2018
Q2 | $5.7M | Buy |
136,696
+21,510
| +19% | +$954K | 0.03% | 286 |
|
|
2018
Q1 | $5.08M | Sell |
115,186
-54,161
| -32% | -$2.75M | 0.03% | 290 |
|
|
2017
Q4 | $8.52M | Sell |
169,347
-88,358
| -34% | -$4.85M | 0.04% | 239 |
|
|
2017
Q3 | $13.1M | Buy |
257,705
+18,545
| +8% | +$971K | 0.07% | 223 |
|
|
2017
Q2 | $12.2M | Buy |
239,160
+13,253
| +6% | +$617K | 0.07% | 216 |
|
|
2017
Q1 | $9.08M | Buy |
225,907
+16,729
| +8% | +$751K | 0.04% | 236 |
|
|
2016
Q4 | $10M | Buy |
209,178
+19,824
| +10% | +$784K | 0.05% | 225 |
|
|
2016
Q3 | $6.94M | Sell |
189,354
-43,037
| -19% | -$1.35M | 0.03% | 247 |
|
|
2016
Q2 | $5.41M | Buy |
232,391
+19,322
| +9% | +$623K | 0.03% | 252 |
|
|
2016
Q1 | $8.63M | Sell |
213,069
-76,475
| -26% | -$3.11M | 0.06% | 189 |
|
|
2015
Q4 | $17.9M | Buy |
289,544
+24,350
| +9% | +$1.31M | 0.14% | 145 |
|
|
2015
Q3 | $10.7M | Sell |
265,194
-32,421
| -11% | -$1.68M | 0.08% | 175 |
|
|
2015
Q2 | $17.1M | Buy |
297,615
+54,250
| +22% | +$3.45M | 0.1% | 163 |
|
|
2015
Q1 | $15.5M | Sell |
243,365
-3,503
| -1% | -$238K | 0.09% | 173 |
|
|
2014
Q4 | $15.2M | Buy |
246,868
+29,062
| +13% | +$1.43M | 0.09% | 164 |
|
|
2014
Q3 | $8.46M | Sell |
217,806
-3,539
| -2% | -$125K | 0.04% | 204 |
|
|
2014
Q2 | $7.63M | Sell |
221,345
-280,943
| -56% | -$8.85M | 0.04% | 215 |
|
|
2014
Q1 | $21.7M | Buy |
502,288
+190,180
| +61% | +$9.22M | 0.11% | 134 |
|
|
2013
Q4 | $12.4M | Buy |
312,108
+38,695
| +14% | +$1.38M | 0.06% | 169 |
|
|
2013
Q3 | $10.3M | Buy |
+273,413
| New | +$8.17M | 0.05% | 174 |
|
Other funds holding IONS
VPM
VCM
VanEck Associates's IONS Position: Q1 2026 in Review
VanEck Associates reduced its Ionis Pharmaceuticals (IONS) stake by 27% in Q1 2026, selling an estimated $994K and leaving 34,505 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #938.
VanEck Associates first reported a position in IONS in Q3 2013 and has held it in 47 quarters since. The position peaked at $21.7M in Q1 2014. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- VanEck Associates held 34,505 shares of Ionis Pharmaceuticals worth $2.59M as of Q1 2026.
- VanEck Associates sold 12,597 Ionis Pharmaceuticals shares in Q1 2026, an estimated $994K.
- Ionis Pharmaceuticals made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #938 holding.
- VanEck Associates first reported a position in Ionis Pharmaceuticals in Q3 2013 and has held it in 47 quarters since.
- VanEck Associates's Ionis Pharmaceuticals position peaked at $21.7M in Q1 2014.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.